Breast cancer related results of groundbreaking napo pharmaceuticals (a jaguar health family company) supported study on quality of life for cancer patients and survivors accepted for presentation at the december 2023 san antonio breast cancer symposium

San francisco, ca / accesswire / november 9, 2023 / napo pharmaceuticals (napo), a jaguar health, inc. (nasdaq:jagx) family company, today announced that the results of "more than a diagnosis: a quality of life survey for individuals with a diagnosis or history of cancer," an online, anonymous napo-supported survey initiative of advocates for collaborative education (ace) to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, have been accepted for presentation at the december 2023 san antonio breast cancer symposium (sabcs). "we are delighted our breast cancer related survey results have been accepted for presentation at sabcs," said advocates for collaborative education founder stacey tinianov, mph.
JAGX Ratings Summary
JAGX Quant Ranking